POM-V Prescription Required Companion Animal

Norbrook Meloxicam 5 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Meloxicam

Form

Injection

Species

Cats Dogs

Manufacturer

Norbrook Laboratories Limited

VMD MA No.

02000/4397

What it's used for

Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation followin...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Norbrook Meloxicam 5 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Dogs:
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal
disorders. Reduction of post-operative pain and inflammation following orthopaedic
and soft tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue
surgery.

Dogs:
Musculo-skeletal disorders: Single subcutaneous injection at a dosage of 0.2 mg
meloxicam/kg bodyweight (i.e. 0.4 ml/10 kg bodyweight). A Meloxicam 1.5 mg/ml oral
suspension may be used for continuation of treatment at a dosage of 0.1 mg
meloxicam/kg bodyweight, 24 hours after administration of the injection.
Reduction of post-operative pain (over a period of 24 hours): Single intravenous or
subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4
ml/10 kg bodyweight) before surgery, for example at the time of induction of
anaesthesia.
Cats:
Reduction of post-operative pain in cats where no oral follow-up treatment is possible
e.g. feral cats:
Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (i.e.
0.06 ml/kg bodyweight) before surgery, for example at the time of induction of
anaesthesia. In this case do not use oral follow up treatment.
Reduction of post-operative pain in cats when administration of meloxicam is to be
continued as an oral follow-up therapy:
Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e.
0.04 ml/kg body weight) before surgery, for example at the time of induction of
anaesthesia.

Amended pages: June 2024
AN: 02252/2023
To continue treatment for up to five days, this initial dose may be followed 24 hours
later by administration of a Meloxicam 0.5 mg/ml oral suspension for cats at a
dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be
administered for up to a total of four doses at 24 hour intervals.
Particular care should be taken with regard to the accuracy of dosing.
A suitably graduated 1 ml syringe should be used for administration of the product to
cats.
Avoid introduction of contamination during use.

Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

Amended pages: June 2024
AN: 02252/2023

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea,
faecal occult blood, apathy and renal failure have been reported very rarely in
spontaneous reports. Elevated liver enzymes have been reported very rarely in
spontaneous reports. In dogs, haemorrhagic diarrhoea, haematemesis and
gastrointestinal ulceration have been reported very rarely in spontaneous reports.
In dogs, these adverse reactions occur generally within the first treatment week and
are in most cases transient and disappear following termination of the treatment but
in very rare cases may be serious or fatal.
Anaphylactoid reactions may occur very rarely in spontaneous reports and should be
treated symptomatically.
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

Amended pages: June 2024
AN: 02252/2023
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

For post-operative pain relief in cats, safety has only been documented after
thiopental/halothane anaesthesia.

Special precautions for use in animals
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of renal toxicity.
During anaesthesia, monitoring and fluid therapy should be considered as standard
practice.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Accidental self-injection may give rise to pain. People with known hypersensitivity to
NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
In view of the risk of accidental self-injection and the known adverse class-effects of
NSAIDs and other prostaglandin inhibitors on pregnancy and/or embryofoetal
development, the veterinary medicinal product should not be administered by
pregnant women or women attempting to conceive.
This product can cause eye irritation. In case of contact with the eyes, immediately
rinse thoroughly with water.
Wash hands after use.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects.
Meloxicam 5 mg/ml solution for injection must not be administered in conjunction
with other NSAIDs or glucocorticosteroids. Concurrent administration of potential
nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged
animals) intravenous or subcutaneous fluid therapy during anaesthesia should be
taken into consideration. When anaesthesia and NSAID are concomitantly
administered, a risk for renal function cannot be excluded.
Pre-treatment with anti-inflammatory substances may result in additional or increased
adverse effects and accordingly a treatment-free period with such drugs should be
observed for at least 24 hours before commencement of treatment. The treatment-
free period, however, should take into account the pharmacological properties of the
products used previously.

Store below 25 °C.
Keep the vial in the outer carton in order to protect from light.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.